Skip to main content

Doxycycline Tied to Lower Risk for C. Difficile in Pneumonia Patients

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 30, 2023.

By Elana Gotkine HealthDay Reporter

THURSDAY, Nov. 30, 2023 -- For patients with community-acquired pneumonia (CAP), doxycycline is associated with a reduced risk for Clostridioides difficile infection (CDI), according to a study published online Nov. 1 in the American Journal of Infection Control.

Ashley L. O'Leary, Pharm.D., from the Veterans Affairs Western New York Healthcare System in Buffalo, and colleagues conducted a retrospective analysis in hospitalized patients in Veterans Affairs Hospitals across the United States to examine whether doxycycline is associated with reduced CDI risk.

During the study timeframe, about 156,107 hospitalized patients received care at a Veterans Affairs Hospital and were diagnosed with CAP. The researchers found that compared with azithromycin, doxycycline used with ceftriaxone for the treatment of pneumonia was associated with a 17 percent reduced risk for CDI. The incidence of CDI was reduced by 45 percent for patients who had a prior history of CDI (odds ratio, 0.55).

"Our analysis found that in patients with a prior history of C. diff, doxycycline was the only factor associated with a reduction in the incidence of new C. diff infections," senior author Kari A. Mergenhagen, Pharm.D., also from the Veterans Affairs of Western New York Healthcare System, said in a statement. "These results suggest that in cases where Legionella pneumonia can be ruled out prior to treatment, patients at increased risk of C. diff may benefit from the use of doxycycline as a first-line agent."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted November 2023

Read this next

Reduced Vancomycin Susceptibility Tied to Poorer C. Diff Outcomes

TUESDAY, April 30, 2024 -- Reduced vancomycin susceptibility is impacting clinical responses among adults with Clostridioides difficile (C. difficile) infection, according to a...

Inappropriate Diagnosis of Pneumonia Common in Hospitalized Adults

WEDNESDAY, March 27, 2024 -- Inappropriate diagnosis of community-acquired pneumonia (CAP) in hospitalized adults is common, especially among older adults and those with dementia...

AGA Recommends Fecal Microbiota Transplant for Recurrent C. Difficile

MONDAY, Feb. 26, 2024 -- Fecal microbiota transplant is recommended on completion of standard-of-care antibiotics to prevent recurrence for adults with recurrent Clostridioides...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.